Search results
FDA Approves First Drug for WHIM Syndrome
MedPage Today· 2 days agoCXCR4 antagonist mavorixafor effectively boosts neutrophils and lymphocytes to reduce infections
Gene expression analyses identify potential drivers of chronic allergic inflammation
Medical Xpress· 8 hours agoCurrently, most therapies for allergic diseases require lifelong treatment. Allergic reactions, characterized by ongoing (type 2) inflammation in response to chronic antigen exposure, underlie ...
W1 professorship for "Congenital and adaptive lymphocyte regulation" - Kiel, Schleswig-Holstein (DE)...
Nature· 2 days agoKiel University (CAU) and the University of Lübeck (UzL) are striving to increase the proportion of qualified female scientists in research and tea...
Lump in Groin: Causes With or Without Pain
Verywell Health via Yahoo News· 7 days agoIt typically begins in lymphocytes, a kind of white blood cell crucial for fighting infections. Lymphoma can manifest as Hodgkin lymphoma or non-Hodgkin...
‘Liquid gold’ could bring new hope to multiple sclerosis patients, study suggests: ‘Profound...
Fox News· 17 hours agoResearchers may have hit "gold" when it comes to the treatment of multiple sclerosis. An...
Microscopic Colitis
Health via Yahoo News· 5 days agoThe two types cause different changes to the colon tissue, but they have identical symptoms and treatments. Lymphocytic Colitis With lymphocytic colitis,...
X4 Pharmaceuticals’ bet on drug for ultra-rare disease pays off with FDA approval - Boston Business...
The Business Journals· 1 day agoX4 Pharmaceuticals (Nasdaq: XFOR) announced on Monday that its drug mavorixafor was given the green...
Weaker skin immunity in males due to androgen effects on ILC2s - Nature Reviews Immunology
Nature· 7 days agoA new study by Yasmine Belkaid and colleagues shows that androgen hormones in male mice negatively regulate type 2 innate lymphoid cells (ILC2s). This leads to a reduction in the accumulation ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 16 hours agoIovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer ...
FDA approves first targeted therapy for WHIM syndrome By Investing.com
Investing.com· 2 days agoFood and Drug Administration (FDA) has approved XOLREMDI™ (mavorixafor) capsules for patients aged...
